Virtual Library

Start Your Search

Jae Jeong Shim



Author of

  • +

    P2.17 - Treatment of Early Stage/Localized Disease (ID 189)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Treatment of Early Stage/Localized Disease
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.17-17 - Clinical Effect of Adjuvant Chemotherapy on Stage IB NSCLC with High-Risk Factors (ID 2089)

      10:15 - 18:15  |  Author(s): Jae Jeong Shim

      • Abstract

      Background

      The efficacy of adjuvant chemotherapy in stage IB NSCLC with high-risk factors remains unclear. We analyze the clinical effect of adjuvant chemotherapy in patients with high-risk factors such as visceral pleural involvement, and micro-papillary type, etc.

      Method

      This study is a multicenter retrospective study. We retrospectively analyzed 269 stage IB NSCLC with high-risk factors receiving lung resection operation from four academic hospitals. We defined the high-risk factors as visceral pleural invasion, vascular invasion, peri-neural invasion, lymphatic invasion, neuroendocrine tumors, and micro-papillary pattern. We used a Kaplan-Meier survival curve to analyze recurrence-free survival and overall survival.

      Result

      There were 139 (51.7%) males and 130 (48.3%) females and the mean patient age was 65.6 ± 9.7 years. There were 142 patients without adjuvant chemotherapy and 127 patients with adjuvant chemotherapy. The median follow-up duration was 31.7 months (range, 2.7 to 60.0 months). And the recurrence-free survival was 48.8 ± 1.8 months in the no adjuvant group, and 54.0 ± 1.5 months in the adjuvant group (P=0.028). And the overall survival was 57.9 ± 0.9 months in the no adjuvant group, and 59.3 ± 0.7 months in the adjuvant group (P=0.124). In the sub-group analysis (visceral pleural involvement group), the recurrence-free survival was 48.2 ± 2.1 months in the no adjuvant group, and 55.3 ± 1.6 months in the adjuvant group (P=0.011)

      Conclusion

      Adjuvant chemotherapy may be useful for patients with Stage IB NSCLC with high-risk factors. And, adjuvant chemotherapy should be considered especially when there is visceral pleural involvement